BCI-121 is a potent SMYD3 inhibitor that weakens the proliferation of a variety of cancer cells.

 

Brand: BCM

 

Target: Histone Methyltransferase

 

Signaling Pathways: Chromatin/Epigenetic

 

In Vitro: BCI-121 significantly reduced the proliferation of HT29 (by 46%) and HCT116 (by 54%) cells at 72 h and decreased the expression levels of SMYD3 target genes. BCI-121 treatment only affected proliferation of cancer cell lines expressing high levels of SMYD3. The high levels of SMYD3 expression detected in OVCAR-3 cells, along with the strong reduction in proliferation rate observed upon BCI-121 treatment.

 

Boiling Point: 576.1±50.0 °C(Predicted)

 

pKa: 13.82±0.70(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol.

 

GHS: GHS07

 

Isomeric SMILES: C1CN(CCC1C(=O)N)CC(=O)NC2=CC=C(C=C2)Br  

 

InChIKey: KSUYPIXCRPCPGF-UHFFFAOYSA-N  

 

InChI: InChI=1S/C14H18BrN3O2/c15-11-1-3-12(4-2-11)17-13(19)9-18-7-5-10(6-8-18)14(16)20/h1-4,10H,5-9H2,(H2,16,20)(H,17,19)

 

Attribute
[Chem Name]	1-[2-(4-bromoanilino)-2-oxoethyl]piperidine-4-carboxamide
[Synonym]	BCI-121
[CAS No.]	432529-82-3
[MDL No.]	MFCD02149239
[Formula]	C14H18BrN3O2
[Molecular]	340.22
[Form]	White to beige powder
[Storage]	Inert atmosphere. Room Temperature

Goods Tag